Mesoblast Limited December 2024 6-K Report: Key Filings & Executive Changes

The document is a Form 6-K filed by Mesoblast Limited with the U.S. Securities and Exchange Commission (SEC) for the month of December 2024. Here are the key pieces of information extracted from the report:

1. Company Details:

• Name: Mesoblast Limited
• Jurisdiction: Australia
• CEO: Silviu Itescu
• Principal Executive Office Address: Level 38, 55 Collins Street, Melbourne 3000, Australia.

2. Filing Information:

• Filing Date: December 23, 2024
• Commission File Number: 001-37626

3. Recent Announcements:

• On December 20, 2024, Mesoblast Limited filed two important documents with the Australian Securities Exchange:
• • Appendix 3Y: Change of directors’ interest notices.
  • Appendix 2A: Application for quotation of securities.
• Both documents are referenced as Exhibit 99.1 and Exhibit 99.2 in the Form 6-K.

4. Signature Section:

• The report was signed by Niva Sivakumar, who is identified as the Company Secretary.

5. Reports and Exhibits:

• The document includes an index to the exhibits filed, which provide additional details on the recent announcements.

Insights:

• The filings indicate ongoing activity regarding changes in the interests of directors, which could reflect strategic financial decisions or shifts in governance.
• The application for quotation of securities suggests possible new issuances or changes in the company’s capital structure, which could impact share liquidity and market perception.
• The report is part of regulatory compliance under the Securities Exchange Act of 1934, highlighting the company's commitment to transparency with investors.

This information is crucial for stakeholders looking to understand Mesoblast Limited's recent developments and regulatory compliance status, potentially influencing investment and operational strategies.